Endeavor

FDA Approves New Approach to Stem Cell Transplants

Roxanne Laveau’s participation in a clinical trial helped lead to the FDA approval of the Orca-T cell therapy for transplant in patients with blood cancers

Study Reveals Key Insights Between New Blood Condition and Lower-Risk Myelodysplastic Syndromes

High-risk CCUS patients by CHRS and CCRS risk stratification tools have similar characteristics and outcomes to patients with lower-risk MDS

New Treatment Reduces Need for Blood Transfusions for Patients with Certain Blood Cancers, Study Shows

Almost 40% of patients with lower risk myelodysplastic syndromes achieved eight-week transfusion independence with imetelstat, study shows

Already Approved Drug Shows Promise in Patients with MDS/MPN Overlapping Syndromes

Moffitt launched trial investigates myelofibrosis drug in rare patient population

USF Alumni Scores Game Ball During Continued Fight with Blood Cancer

Woman, 36, with slight exhaustion went in for routine physical and came out with cancer diagnosis

Molecular Risk Model Better Predicts Outcomes in Rare Blood Cancer

New model can help dictate treatment decisions in chronic myelomonocytic leukemia

Personal Experiences with Cancer Care Shape Design of New Hospital

For the patients, families and team members who helped design the new Moffitt McKinley Hospital, the details make the difference

New Therapy Shows Promise for Myelodysplastic Syndrome Patients

SX-682 works by targeting both adverse immune cells and cancer cells

Moffitt Investigates First-of-Its-Kind Cellular Therapy in MDS Patients

Novel approach uses mismatched donor lymphocytes to activate patient’s immune system